Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

VAXAR PLUS 15 MG/10 MG COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/VAXAR PLUS 15 MG/10 MG COMPRIMIDOS

Approved

STANDARD

VAXAR PLUS 15 MG/10 MG COMPRIMIDOS

Adamed Laboratorios S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 29, 2024
Approval ID: d689d21fa27283a1
Company: Adamed Laboratorios S.L.U.
Type: Standard

Approval Details

Approval Id: d689d21fa27283a1
Drug Cima Aemps Name: VAXAR PLUS 15 MG/10 MG COMPRIMIDOS
Register Number: 89602
Holder Company Name: Adamed Laboratorios S.L.U.
Marketing Company Name: Adamed Laboratorios S.L.U.
Authorization Date: 2024-05-29
Dosage Form: COMPRIMIDO
Dose: 15 mg/10 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Adamed Laboratorios S.L.U.

Active Ingredients

ROSUVASTATINA CALCICA

15,60 mg

EZETIMIBA

10 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 29, 2024

Approval ID

d689d21fa27283a1

Type

Standard

Back to CIMA-AEMPS Approvals